Research Development Core
研究开发核心
基本信息
- 批准号:10649616
- 负责人:
- 金额:$ 78.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-15 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
ABSTRACT
The Research Development Core (RDC) is an integrated platform that provides access to the USC-Buck NSC
Resource Cores (RCs) and represents an innovative approach to advance geroscience training and mentoring,
primarily to junior faculty and new investigators especially from institutions that lack aging programs. The RDC
will employ three primary mechanisms to achieve this goal: the first is to provide access to USC and Buck
Institute expertise and technologies by funding and innovative research in aging sabbaticals scheme. We will
also provide funding for innovative pilot projects and vouchers to ensure that the NSC course will used by
investigators from across the country, especially those new to aging field. The proposed USC-Buck NSC
Research Development Core (RDC) is significant because it will advance the science of aging, provide much-
needed training and professional development of early career scientists, provide access to technology
platforms and promote the aging field beyond its current boundaries.
抽象的
研究开发核心(RDC)是一个集成平台,可访问USC-Buck NSC
资源核心(RCS),代表了一种创新的方法来推进Geroscience培训和指导,
主要是针对初级教师和新调查人员,尤其是来自缺乏老化计划的机构。 RDC
将采用三种主要机制来实现这一目标:第一个是提供对USC和Buck的访问权限
通过资助和创新研究的衰老休假计划进行的专业知识和技术。我们将
还为创新的试点项目和优惠券提供资金,以确保NSC课程将由
来自全国各地的调查人员,尤其是那些刚开始衰老的人。拟议的USC-Buck NSC
研究发展核心(RDC)之所
早期职业科学家需要培训和专业发展,提供技术访问
平台并促进衰老领域超出其当前边界。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据
数据更新时间:2024-06-01
Julie Kay Andersen的其他基金
Novel mitochondria-to-lysosome crosstalk contributes to lysosomal dysfunction during aging
新型线粒体与溶酶体串扰导致衰老过程中溶酶体功能障碍
- 批准号:1072305010723050
- 财政年份:2023
- 资助金额:$ 78.81万$ 78.81万
- 项目类别:
Neuronal FXR as a potential therapeutic target for Alzheimer's disease
神经元 FXR 作为阿尔茨海默病的潜在治疗靶点
- 批准号:1037486210374862
- 财政年份:2020
- 资助金额:$ 78.81万$ 78.81万
- 项目类别:
Neuronal FXR as a potential therapeutic target for Alzheimer's disease
神经元 FXR 作为阿尔茨海默病的潜在治疗靶点
- 批准号:1060098910600989
- 财政年份:2020
- 资助金额:$ 78.81万$ 78.81万
- 项目类别:
Cellular senescence and Alzheimer's disease
细胞衰老和阿尔茨海默病
- 批准号:1004432810044328
- 财政年份:2020
- 资助金额:$ 78.81万$ 78.81万
- 项目类别:
New mechanistic insights into how the gut metabolite urolithin A extends lifespan and prevents AD
关于肠道代谢物尿石素 A 如何延长寿命和预防 AD 的新机制见解
- 批准号:1061489610614896
- 财政年份:2018
- 资助金额:$ 78.81万$ 78.81万
- 项目类别:
Environmental exposure and astrocytic senescence: novel link to PD?
环境暴露和星形细胞衰老:与 PD 的新联系?
- 批准号:87586278758627
- 财政年份:2014
- 资助金额:$ 78.81万$ 78.81万
- 项目类别:
2011 Oxidative Stress and Disease Gordon Research Conference
2011 氧化应激与疾病戈登研究会议
- 批准号:80456548045654
- 财政年份:2010
- 资助金额:$ 78.81万$ 78.81万
- 项目类别:
2011 Oxidative Stress and Disease Gordon Research Conference
2011 氧化应激与疾病戈登研究会议
- 批准号:82095208209520
- 财政年份:2010
- 资助金额:$ 78.81万$ 78.81万
- 项目类别:
2011 Oxidative Stress and Disease Gordon Research Conference
2011 氧化应激与疾病戈登研究会议
- 批准号:82141988214198
- 财政年份:2010
- 资助金额:$ 78.81万$ 78.81万
- 项目类别:
相似海外基金
The Role of Lipids in Alzheimer's Disease and Related Dementias among Black Americans: Examining Lifecouse Mechanisms
脂质在美国黑人阿尔茨海默病和相关痴呆中的作用:检查生命机制
- 批准号:1064334410643344
- 财政年份:2023
- 资助金额:$ 78.81万$ 78.81万
- 项目类别:
Enhancing Participation of Historically Minoritized Groups in Alzheimer Disease and Related Dementias Research
加强历史上少数群体对阿尔茨海默病和相关痴呆症研究的参与
- 批准号:1075246110752461
- 财政年份:2023
- 资助金额:$ 78.81万$ 78.81万
- 项目类别:
Interactions of SARS-CoV-2 infection and genetic variation on the risk of cognitive decline and Alzheimer’s disease in Ancestral and Admixed Populations
SARS-CoV-2 感染和遗传变异的相互作用对祖先和混血人群认知能力下降和阿尔茨海默病风险的影响
- 批准号:1062850510628505
- 财政年份:2023
- 资助金额:$ 78.81万$ 78.81万
- 项目类别:
Racial Disparities in Alzheimer's Disease and Related Dementias: The Role of School Segregation and Experiences of Discrimination
阿尔茨海默病和相关痴呆症的种族差异:学校隔离的作用和歧视经历
- 批准号:1060636210606362
- 财政年份:2023
- 资助金额:$ 78.81万$ 78.81万
- 项目类别: